Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease

被引:66
作者
Girgis, RE
Gugnani, MK
Abrams, J
Mayes, MD
机构
[1] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21287 USA
[2] Wayne State Univ, Sch Med, Dept Internal Med, Div Rheumatol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Biostat, Detroit, MI USA
关键词
interstitial lung disease; nitric oxide; pulmonary hypentension; scleroderma;
D O I
10.1164/rccm.2104003
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
We partitioned exhaled nitric oxide (NO) into alveolar concentration (CA) and conducting airway flux (JNO(air,max)) in scleroderma (SSc) lung disease and hypothesized that CA would be elevated. Twenty patients with SSc, 15 with interstitial lung disease (SSc-ILD) alone, and 5 with pulmonary hypertension (SSc-PH) were compared with 20 control subjects. CA and JNO(air,max) were derived from the slope and y intercept, respectively, of the NO output versus expiratory flow rate ((V) over dot exh) relationship obtained by measuring exhaled NO (FENO) at multiple (V) over dot exh values of 50-200 ml/second. There were no significant differences in FENO at any (V) over dot exh between the SSc group and control subjects. JNO(air,max) was reduced (0.6 +/- 0.1 versus 1.2 +/- 0.2 nl of NO per second; p = 0.01), whereas CA was increased (4.7 +/- 0.5 versus 1.8 +/- 0.2 ppb; p < 0.001) in the SSc group compared with control subjects. No differences were noted between SSc-ILD and SSc-PH. There was a negative correlation between CA and DLCO among the patients with SSc (R = -0.66, p = 0.002). We conclude that CA IS increased whereas JNO(air,max) is decreased in SSc-ILD and SSc-PH. A reduced diffusing capacity of NO from the alveolar space into the blood could explain the observed increase in CA.
引用
收藏
页码:1587 / 1591
页数:5
相关论文
共 47 条
[1]
Andersen GN, 2000, ARTHRITIS RHEUM-US, V43, P1085
[2]
[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185
[3]
[Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104
[4]
[Anonymous], 1987, Am Rev Respir Dis, V136, P1285
[5]
Black C. M., 1996, SYSTEMIC SCLEROSIS, P299
[6]
BORLAND CDR, 1989, EUR RESPIR J, V2, P56
[7]
Clements PJ, 1999, ARTHRITIS RHEUM-US, V42, P1194, DOI 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO
[8]
2-7
[9]
Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection [J].
Cool, CD ;
Kennedy, D ;
Voelkel, NF ;
Tuder, RM .
HUMAN PATHOLOGY, 1997, 28 (04) :434-442
[10]
Cotton SA, 1999, J PATHOL, V189, P273